Idorsia Ltd Stock price

Equities

IDIA

CH0363463438

Biotechnology & Medical Research

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
2.828 CHF +9.95% Intraday chart for Idorsia Ltd +32.89% +33.77%
Sales 2023 * 119M 132M Sales 2024 * 214M 238M Capitalization 505M 560M
Net income 2023 * -407M -451M Net income 2024 * -401M -444M EV / Sales 2023 * 12.8 x
Net Debt 2023 * 1.02B 1.13B Net Debt 2024 * 1.22B 1.35B EV / Sales 2024 * 8.05 x
P/E ratio 2023 *
-1.36 x
P/E ratio 2024 *
-1.98 x
Employees 650
Yield 2023 *
-
Yield 2024 *
-
Free-Float 58.67%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Idorsia Ltd

1 day+9.95%
1 week+32.89%
Current month+26.70%
1 month+8.35%
3 months+28.55%
6 months+9.95%
Current year+33.77%
More quotes
1 week
2.12
Extreme 2.118
2.97
1 month
1.65
Extreme 1.65
2.97
Current year
1.29
Extreme 1.294
3.70
1 year
1.29
Extreme 1.294
10.37
3 years
1.29
Extreme 1.294
27.08
5 years
1.29
Extreme 1.294
33.88
10 years
1.29
Extreme 1.294
33.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 17-05-31
Director of Finance/CFO 60 17-05-31
Chief Tech/Sci/R&D Officer 67 17-03-02
Members of the board TitleAgeSince
Director/Board Member 65 20-05-12
Director/Board Member 68 21-05-11
Chief Executive Officer 68 17-05-31
More insiders
Date Price Change Volume
24-03-28 2.828 +9.95% 1,874,799
24-03-27 2.572 +1.34% 869,081
24-03-26 2.538 +13.51% 1,062,979
24-03-25 2.236 +5.17% 512,686
24-03-22 2.126 -0.09% 765,773

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.828 CHF
Average target price
2.099 CHF
Spread / Average Target
-25.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Idorsia Ltd - Swiss Exchange